GlassScriptPhysician profile
Elizabeth Powell
NPI 1063934081
$6,131.80
in general payments reported to CMS, 2019-2025
37 companies · $954 in 2025
The $954 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,102 · 2022: $1,124 · 2023: $1,475 · 2024: $1,477 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,603.75 | 2021-2025 | |
| Novo Nordisk INC | $1,125.97 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $596.02 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $353.24 | 2021-2025 | |
| Amgen INC. | $287.16 | 2021-2025 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $236.41 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $213.11 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $208.03 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.17 | 2021-2023 | Trulance, Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $145.87 | 2022 | |
| Merck Sharp & Dohme LLC | $132.12 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Axsome Therapeutics, INC. | $116.14 | 2025 | Symbravo, Auvelity |
| Glaxosmithkline, LLC. | $115.97 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $111.38 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $77.71 | 2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.